Trial reportPloS one2019
Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.
Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- Guideline
- Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study.Haematologica · 2024Trial
- Risk and impact of invasive fungal infections in patients with multiple myeloma.Annals of hematology · 2020Trial
- Diabetes mellitus in multiple myeloma and related plasma cell disorders: a review of risk, prognosis, and outcomes.Blood cancer journal · 2026Review
- Cytomegalovirus infection after autologous transplantation in patients with multiple myeloma exposed to daratumumab.Bone marrow transplantation · 2025Article
- Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review.Frontiers in immunology · 2025Review
- Decoding NAD+ Metabolism in COVID-19: Implications for Immune Modulation and Therapy.Vaccines · 2024Review
- Article
- IgG replacement in multiple myeloma.Blood cancer journal · 2024Review
- Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens.Cancer medicine · 2024Article
- Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden.Cancer medicine · 2024Article
- Outcomes of COVID-19 in multiple myeloma patients treated with daratumumab.Cancer science · 2024Article
- Death Caused by Disseminated Herpes Zoster in a Patient with Multiple Myeloma: A Case Report and Literature Review.Clinical, cosmetic and investigational dermatology · 2024Article
- Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma.Frontiers in cell and developmental biology · 2024Review
- Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison.Cureus · 2023Article
- B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses.Life science alliance · 2023Article
- Review
- Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15.Blood advances · 2023Article
- Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma.Frontiers in oncology · 2023Article
- State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond.Heart failure reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment with Daratumumab (Dara), a monoclonal anti-CD38 antibody of IgG1 subtype, is effective in patients with multiple myeloma (MM). However, Dara also impairs the cellular immunity, which in turn may lead to higher susceptibility to infections. The exact link between immune impairment and infectious complications is unclear. In this study, we report that nine out of 23 patients (39%) with progressive MM had infectious complications after Dara treatment. Five of these patients had viral infections, two developed with bacterial infections and two with both bacterial and viral infections. Two of the viral infections were exogenous, i.e. acute respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), while five consisted of reactivations, i.e. one herpes simplex (HSV), 1 varicella-zoster (VZV) and three cytomegalovirus (CMV). Infections were solely seen in patients with partial response or worse. Assessment of circulating lymphocytes indicated a selective depletion of NK cells and viral reactivation after Dara treatment, however this finding does not exclude the multiple components of viral immune-surveillance that may get disabled during this monoclonal treatment in this patient cohort. These results suggest that the use of antiviral and antibacterial prophylaxis and screening of the patients should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.